_
Israel Biotech Showcase: Pharmos LTD
Organization: PHARMOS LTD. , Contact: Name: Prof. Haim Aviv , Chairman & CEO
Address: Kiryat Weizmann Rehovot ISRAEL, 76326 , Telephone: 08-9409679 , Fax: 08-9409686 , Email: pars@pharmos.com , WEB site: www.pharmoscorp.com
GENERAL INFORMATION
Established: 1990 , Type: Industry , Ownership: Private , Parent: Pharmos Corporation , Employees: 55
Core business: Therapeutics for treatment of a range of neurological disorders such as stroke, neuropathic pain, Parkinson's disease and other CNS and peripheral neuro-inflammatory indications.
Overview: Pharmos Corporation is a bio-pharmaceutical company that develops and commercializes products for the central nervous system (CNS), neurological and other key healthcare markets.
Untill recently the leading product in development was dexanabinol, but the drug failed the international Phase III
clinical study for the treatment of severe TBI in over 45 centers in 8 European countries and Israel.
With the aid of computational chemistry, Pharmos has constructed a library of dextrocannabinoid compounds comprising two major chemical groups. The first is the tricyclic family of compounds, of which dexanabinol is the prototype. These compounds have the generic ability to inhibit NMDA receptors and to block COX-2, cytokines and chemokine activation, thereby acting as powerful anti-inflammatory and neuroprotective agents against diseases
such as stroke, neuropathic pain and other neuro-inflammatory indications.
The second group is the bicyclic family of compounds, which specifically bind to CB2 receptors. Because CB2 receptors are present in all cells of the immune system, Pharmos is evaluating the potential of bicyclic dextrocannabinoid compounds as modulators of the immune system and for their affect on
auto-immune diseases.
Pharmos is actively studying compounds from its dextrocannabinoid library in pre-clinical programs targeting various CNS and peripheral disorders, including stroke, neuropathic pain, Parkinson's disease, renal ischemia and others.
AVAILABLE R&D CAPABILITIES:
Expertise: R&D objects: Development of neurological pharmaceuticals, using innovative drug design technologies.
R&D markets: Neurological disorders Sci. discipline: Pharmaceuticals, Pharmacology, Clinical trials.
Available R&D facilities: Annual R&D expenditure (MU$): 5,000 ; R&D employees: 43 ; R&D professionals: 21
Source: Pharmos LTD: Invitation for technological cooperation. Matimop.org.il web site
Address: Kiryat Weizmann Rehovot ISRAEL, 76326 , Telephone: 08-9409679 , Fax: 08-9409686 , Email: pars@pharmos.com , WEB site: www.pharmoscorp.com
GENERAL INFORMATION
Established: 1990 , Type: Industry , Ownership: Private , Parent: Pharmos Corporation , Employees: 55
Core business: Therapeutics for treatment of a range of neurological disorders such as stroke, neuropathic pain, Parkinson's disease and other CNS and peripheral neuro-inflammatory indications.
Overview: Pharmos Corporation is a bio-pharmaceutical company that develops and commercializes products for the central nervous system (CNS), neurological and other key healthcare markets.
Untill recently the leading product in development was dexanabinol, but the drug failed the international Phase III
clinical study for the treatment of severe TBI in over 45 centers in 8 European countries and Israel.
With the aid of computational chemistry, Pharmos has constructed a library of dextrocannabinoid compounds comprising two major chemical groups. The first is the tricyclic family of compounds, of which dexanabinol is the prototype. These compounds have the generic ability to inhibit NMDA receptors and to block COX-2, cytokines and chemokine activation, thereby acting as powerful anti-inflammatory and neuroprotective agents against diseases
such as stroke, neuropathic pain and other neuro-inflammatory indications.
The second group is the bicyclic family of compounds, which specifically bind to CB2 receptors. Because CB2 receptors are present in all cells of the immune system, Pharmos is evaluating the potential of bicyclic dextrocannabinoid compounds as modulators of the immune system and for their affect on
auto-immune diseases.
Pharmos is actively studying compounds from its dextrocannabinoid library in pre-clinical programs targeting various CNS and peripheral disorders, including stroke, neuropathic pain, Parkinson's disease, renal ischemia and others.
AVAILABLE R&D CAPABILITIES:
Expertise: R&D objects: Development of neurological pharmaceuticals, using innovative drug design technologies.
R&D markets: Neurological disorders Sci. discipline: Pharmaceuticals, Pharmacology, Clinical trials.
Available R&D facilities: Annual R&D expenditure (MU$): 5,000 ; R&D employees: 43 ; R&D professionals: 21
Source: Pharmos LTD: Invitation for technological cooperation. Matimop.org.il web site
posted by BioMedMarket.Info @ 5.7.05
0 Comments:
Post a Comment
<< Home